reports
EQS-News: KAP REACHES 2023 ADJUSTED GUIDANCE FORECAST AND PROJECTS SIG...
EQS-News: KAP AG / Key word(s): Annual Report KAP REACHES 2023 ADJUSTED GUIDANCE FORECAST AND PROJECTS SIGNIFICANTLY RISING EBITDA 26.04.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. KAP REACHES 2023 ADJUSTED GUIDANCE FORECAST AND PROJECTS SIGNIFICANTLY RISING EBITDA Revenue of €316.7 million and normalised EBITDA of €15.6 million (adjusted for the companies sold in April 2023) Negative factors include supply chain issues and negative macroeconomic developments in the construction sector and the automotive sector Struct...
EQS-News: KAP ERREICHT ANGEPASSTE PROGNOSE IN 2023 UND RECHNET MIT DEU...
EQS-News: KAP AG / Schlagwort(e): Jahresbericht KAP ERREICHT ANGEPASSTE PROGNOSE IN 2023 UND RECHNET MIT DEUTLICH STEIGENDEM EBITDA 26.04.2024 / 08:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. KAP ERREICHT ANGEPASSTE PROGNOSE IN 2023 UND RECHNET MIT DEUTLICH STEIGENDEM EBITDA Umsatz: 316,7 Mio. EUR, normalisiertes EBITDA: 15,6 Mio. EUR (bereinigt um die im April 2023 verkauften Gesellschaften) Belastungen auch durch Lieferkettenproblematik sowie negative Konjunktur im Bauwesen und dem Automobilsektor Erste Erfolge der stru...
Range Resources Corp : 1 director
A director at Range Resources Corp sold 15,978 shares at 37.748USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Markus Henriksson
- Viktor Stenlöf
- Chaima Ferrandon
- Sven Edelfelt
Saint-Gobain : Dans l’inflexion, la vérité éclatera
>CA en ligne avec les attentes et amélioration des volumes sous-jacents - CA T1 2024 à 11 356 M€ (-8.5% en réel, -5.8% à pcc dont -1.1% en prix et -4.7% en volume) soit 1% au-dessus du consensus. En plus d’un léger recul des prix pénalisant la croissance organique, le groupe a enregistré une baisse de ses volumes de 4.7% (après -4.8% au T4 et -5.0% au T3) pénalisé par le logement neuf surtout en Europe. Au T1, les baisses de volumes ressortent à 9.3% (Europe du Nord) ...
- Luis de Toledo Heras
Iberpapel : Anticipated deterioration on normalising energy contributi...
>Normalising results on lower energy contribution - Uninspiring Q1 2024 results following the extraordinary contribution from the energy activities in Q4 2023 with the low prices of energy forcing the group to moderate the production at the gas cogeneration plant in the period. Results reflect the normalisation in demand patterns in paper (reactivation of demand and production in Europe after the sharp destocking process experienced in 2023) and a recovery in paper pr...
- Klaus Ringel
DEUTZ AG : Future profitable growth prospects not adequately discounte...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - >A strong non-captive engine manufacturer with leading market positions - Deutz AG is the oldest independent engine manufacturer in the wo...
- Martin Marandon-Carlhian
- Stephane Houri
STMicroelectronics N.V. : Significant reset in expectations, with a lo...
>We lower our estimates by 33% to take into account the new scenario for 2024 and cut our target price to € 48 (vs € 50), but remain at Outperform - Following the publication of lower-than-expected Q1 2024 results, Q2 guidance that was also lower than expected and a drastic downward revision to the 2024 guidance, we cut our estimates by an average of 33%, and lower our target price (average of a DCF and SOP) to € 48 (vs € 50). The reset is significant and Q2 2024 shou...
EQS-News: TRATON GROUP reports successful start to 2024 with higher sa...
EQS-News: TRATON SE / Key word(s): Quarterly / Interim Statement TRATON GROUP reports successful start to 2024 with higher sales revenue, earnings, and profitability 26.04.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. IR release TRATON GROUP reports successful start to 2024 with higher sales revenue, earnings, and profitability TRATON GROUP sales revenue grew by 5% to €11.8 billion in the first quarter Adjusted operating result rose by €171 million to €1,106 million Adjusted operating return on sales came in 1 percenta...
Cairn Homes Plc: Transaction in Own Shares
Cairn Homes Plc (CRN) Cairn Homes Plc: Transaction in Own Shares 26-Apr-2024 / 07:00 GMT/BST 26 April 2024 Cairn Homes plc (the “Company”) Transaction in own shares The Company announces that on 25th of April 2024 it purchased a total of 100,000 of its ordinary shares of EUR 0.001 each (the "ordinary shares") on Euronext Dublin and the London Stock Exchange through the Company's broker Goodbody Stockbrokers UC (“Goodbody”), as detailed below. The repurchased shares will be cancelled. Euronext Dublin London Stock Exchange Number ...
EQS-News: TRATON GROUP startet erfolgreich ins Jahr 2024 und steigert ...
EQS-News: TRATON SE / Schlagwort(e): Quartals-/Zwischenmitteilung TRATON GROUP startet erfolgreich ins Jahr 2024 und steigert Umsatz, Ergebnis und Rendite 26.04.2024 / 08:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. IR-Mitteilung TRATON GROUP startet erfolgreich ins Jahr 2024 und steigert Umsatz, Ergebnis und Rendite Umsatz der TRATON GROUP legt im ersten Quartal 2024 um 5 % auf 11,8 Mrd € zu Bereinigtes Operatives Ergebnis wächst um 171 Mio auf 1.106 Mio € Bereinigte Operative Rendite steigt um 1 Prozentpunkt auf 9,4 % ...
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- ABGSC Capital Goods Research
- Karl Bokvist
- Juan Ros-Padilla
Laboratorios Rovi : Pre-filled syringes contract with a global pharma
>Agreement to manufacture pre-filled syringes for a global pharma company - Rovi has announced that its subsidiary ROIS has entered into an agreement to support the manufacture of pre-filled syringes for a global pharmaceutical company. Under the terms of the agreement, ROIS will provide a high-speed production line at its San Sebastián de los Reyes facility, with an estimated annual capacity of 100 million units. The agreement includes the technology transfer for ase...
- Eya Hmaied
- Jerôme Bodin
Atresmedia : Results ahead of expectations thanks to a particularly go...
>Very positive advertising trend in Q1 - Atresmedia yesterday reported Q1 2024 results that topped our expectations and those of the consensus with EBITDA of € 50m vs € 46m forecast by ODDO BHF and € 44m by the consensus. The surprise was the advertising trend in Q1, which was very solid and well ahead of expectations at +14.4% vs 9%e. Advertising momentum at the start of the year in Spain seems to have been better than elsewhere in Europe. This is thanks to very goo...
- Delphine Brault
- Quentin Borie
Schneider Electric : Volumes holding up in Q1, price normalising
>Q1 sales: 5.3% organic growth with 4%+ for volumes - Q1 sales, reported yesterday, were broadly in line with expectations (0.4% above by value, but with slightly better organic growth). Sales grew by 5.3% in organic terms vs 4.5% expected by the consensus (see our flash published yesterday “Q1 2024 sales slightly ahead of expectations, which had adjusted downwards”). This 5.3% breaks down into 1% of pricing (on the product portion) and over 4% of volumes (vs over 5% ...
- Jean Danjou
Hermes International : Fine growth in Q1 but momentum set to slow
>Flattering growth in Q1 at +17% at CER but excluding the internalisation effect in the UAE (c. 2 pts), fairly close to our expectations - Hermès reported Q1 sales of € 3,805m, or up 12.6% on a reported basis and +17% at constant exchange rates. Our estimate at € 3,713m pointed to organic growth of 13.5% and the Visible Alpha consensus at € 3,683m suggested around +13%. It should be noted that the re-internalisation of the stores in the UAE (conversion from whole...
AS Tallinna Vesi will hold an Investor Conference Webinar to introduce...
AS Tallinna Vesi will hold an Investor Conference Webinar to introduce the results for the 1st quarter of 2024 AS Tallinna Vesi invites its shareholders, investors, analysts, and other stakeholders to join its investor conference webinar, introducing the results for the 1st quarter and 3 months of 2024. The webinar is scheduled for 3 May 2024 at 11:00 am (EET) and will be held in English. The webinar will be hosted by Aleksandr Timofejev, Chief Executive Officer, and Taavi Gröön, Chief Financial Officer. The questions will be answered by Aleksandr Timofejev and Taavi Gröön after the presen...
Nexstim Oyj:n liiketoiminnan päivitys, tammi-maaliskuu 2024
Nexstim Oyj:n liiketoiminnan päivitys, tammi-maaliskuu 2024 Lehdistötiedote, Helsinki, 26.04.2024, klo. 09.00 (EEST) Nexstim Oyj:n liiketoiminnan päivitys, tammi-maaliskuu 2024 Nexstim Oyj (NXTMH:HEX) (jäljempänä ”Nexstim” tai ”Yhtiö”) kertoo Yhtiön liiketoiminnan kohokohdista vuoden 2024 ensimmäisellä vuosineljänneksellä. Toimitusjohtaja Mikko Karvisen liiketoiminnan päivitys Strategisen päätavoitteemme mukaisesti olemme alkuvuodesta 2024 jatkaneet keskittymistä kannattavaan liikevaihdon kasvuun. Tämän vuoden alun uusien laitteistojen myynti on ollut hiljaista, mikä on tyypillistä otta...
Nexstim Plc Business Update Q1 2024
Nexstim Plc Business Update Q1 2024 Press release, Helsinki, 26 April 2024 at 9 AM (EEST) Nexstim Plc Business Update Q1 2024 Nexstim Plc (NXTMH:HEX) (”Nexstim” or ”Company”) announces the key highlights of the Company’s business operations during Q1 2024. CEO Mikko Karvinen’s Business Update In line with our main strategic objective, we have continued to focus on profitable net sales growth. The sales of new systems at the beginning of this year has been slow, which is typical considering that hospitals' budgets focus on purchases towards the end of the year. We continued to grow our D...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.